DiamiR and AlzLabs Partner to Develop Blood-Based Alzheimer's Biomarkers
The Aptorum Group subsidiary DiamiR Biosciences is teaming with AlzLabs Precision Diagnostics to advance protein and microRNA blood tests for Alzheimer's detection.
A new collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics signals a growing push to make Alzheimer's disease detectable through a simple blood draw rather than costly or invasive brain imaging and spinal procedures. The partnership, announced Monday under the umbrella of Nasdaq-listed Aptorum Group, will focus on generating protein and microRNA biomarker data from blood samples — a scientific avenue that researchers believe could dramatically lower the barrier to early diagnosis.
MicroRNA markers and protein signatures in blood have emerged as among the most promising frontiers in neurology diagnostics, because they may reflect brain changes years before cognitive symptoms appear. DiamiR, which specializes in blood-based diagnostic tests for brain health and other conditions, brings that biomarker expertise to the table, while AlzLabs Precision Diagnostics contributes its Alzheimer's-specific research infrastructure. Together, the pairing represents a convergence of molecular biology and clinical diagnostics that could accelerate the path toward a scalable, accessible screening tool.
Read more CRH Acquires Arcosa in $8.5 Billion Infrastructure Deal →
The significance of this collaboration extends beyond the two companies involved. Alzheimer's disease affects tens of millions globally, and the absence of affordable, minimally invasive diagnostic options has long hampered both early intervention and clinical trial recruitment. Blood-based biomarkers, if validated at scale, could reshape how neurologists stratify patients and how drug developers identify trial-eligible populations — giving the broader Alzheimer's research ecosystem a critical new resource.
Aptorum Group, the clinical-stage biopharmaceutical firm that counts DiamiR among its portfolio assets, trades on Nasdaq under the ticker APM. The company has positioned itself around addressing unmet medical needs, and a validated blood biomarker panel for Alzheimer's would represent a substantial commercial and clinical milestone. The collaboration remains in its data-generation phase, meaning near-term milestones will center on scientific output rather than regulatory submissions.
Continue reading at GlobalNewswire.
